Clinical trial NCT03045692: Assessment of Kidney Function for Drug Dosage Adjustments in Critically Ill Patients
Official title: Reliable Methods to Assess Kidney Function for Drug Dosage Adjustments in Critically Ill Patients - Comparison of Timed Clearance of Creatinine and Creatinine Based Estimated GFR
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: ICU Patients
Keywords: drug dosing, eGFR, CCr
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2017-02-07
Enrollment: 172
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double blind randomized trial
Primary purpose: TREATMENT

Brief summary: The aim of the study is to determine if colistin dosage adjustment using 4hr CrCl contribute to better clinical outcomes compared with drug dosage adjustment using eGFR in critical ill patients. In control group, colistin maintenance dosage will be decided using serum creatinine based eGFR (in ml/min). In study group, colistin maintenance dosage will be decided using 4hr CrCl.

Detailed description: 1. Screening periods (From 'informed consents' to 'randomization')

   * Check of inclusion/exclusion criteria ② Measurement of 4hr CrCl \& eGFR in ml/min

     * calculation of maintenance dose ③ Baseline characteristics \& laboratory findings ④ Randomization
2. Colistin dosage Loading dose : 5 x body weight (not exceeding 300mg) Maintenance dose (after 12 hours from loading dose)

   : 2.5 x (\[1.5 x GFR\] + 30) (divided doses every 12hours), GFR in ml/min

   During the study period, daily morning serm creatinine levels are measured. Whenever serum creatinine concentration changes by more than 10% compared with baseline, 4hr CrCl will be mearued. At the every time of 4hr CrCl measurements, colistin dose wil be modified according to new GFR values (4hr CrCl in study group, eGFR in control group)
3. Blood sampling for Colistin trough level measurement Peripheral blood will be sampled twice between 72 hrs and 144 hours after loading dose, just before colistin infusion. The samples were collected in heparined tubes and centrifuged at 4 °C within 1 hr of collection. The resulting plasma was stored at - 70°C . And two values will be averaged out.
4. End of randomization (7 days after colistin initiation) ① Nephrotoxicity ② Treatment outcome microbiological outcome: eradication / no eradication clinical outcome: complete response / partial response / treatment failure

Eligibility criteria: Inclusion Criteria:

1. Patients aged over 18
2. Patients in intensive care unit received colistin for the microbiologically documented cases associated with carbapenem-resistant gram negative bacilli.

Exclusion Criteria:

1. Patients who received colistin empirically.
2. Patients who received renal replacement therapy due to acute kidney injury or end-stage renal disease
3. Patients whose urine output was less than 0.5cc/kg/hr for 6 hrs
4. Patients who underwent hematopoietic stem cell transplantation
5. Patients who disagree with this study.

Primary outcomes:
measure: composite outcome (combination of nephrotoxicity or treatment failure)
timeFrame: 7 days after colistin initiation
Secondary outcomes:
measure: colistin trough level, renal clearance of colistin
timeFrame: 7 days after colistin initiation
measure: ICU stay duration
timeFrame: till discharge (Max. 3 months)
measure: Total duration of colistin treatment
timeFrame: till discharge (Max. 3 months)
measure: Need for renal replacement therapy
timeFrame: 7 days after colistin initiation
measure: In-ICU mortality (infection-attributed mortality)
timeFrame: till discharge (Max. 3 months)
Other outcomes:
Locations:
Study officials:
References: